{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-24-000054","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.133574+00:00","generated_at":"2026-06-02T19:34:17.893500+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immuneering reports Q1 net loss $14.3M; Phase 2a data for IMM-1-104 expected in 2024","bullets":["Net loss $14.3M ($0.49/share) vs $13.6M ($0.51) Q1 2023; R&D expense $11.2M up from $10.2M.","Phase 1 data for IMM-1-104 shows well-tolerated safety; target lesion regression in >50% of patients at 320mg.","First patient dosed in Phase 2a of IMM-1-104; initial data from multiple arms expected in 2024.","First patient dosed in Phase 1/2a of IMM-6-415 (RAF/RAS mutations); initial PK/PD/safety data expected 2024.","FDA Fast Track designation for IMM-1-104 in pancreatic cancer; cash $71.3M expected to fund operations into H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-24-000054","json":"https://secwatch.observer/filing/0001790340-24-000054.json","markdown":"https://secwatch.observer/filing/0001790340-24-000054.md","text":"https://secwatch.observer/filing/0001790340-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000054/0001790340-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000054/imrx-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:34:17.893500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d58b2dbc9ff4b0e05d9cdfddc1bd944f5b6becf0","claim":"Immuneering Corp reported the first quarter ended March 31, 2024 results: net income Net loss attributable to common stockholders was $14.3 million, or $0.49 per share, EPS $0.49 per share.","evidence_excerpt":"Immuneering Corporation (the “Company”) announced its financial results for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000054/0001790340-24-000054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss attributable to common stockholders was $14.3 million, or $0.49 per share"},{"label":"EPS","value":"$0.49 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}